Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 595-599

  Martínez, Antonio ^a,b   Sánchez, Manuel ^a  

^a Instituto Gallego de Oftalmologia   (Spain)

^b NONE   (Spain)

Author keywords

Dorzolamide timolol fixed combination; Non responders; Primary open angle glaucoma; Prostaglandin analogs; Prostamides; Pseudoexfoliative glaucoma

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; PROSTAGLANDIN DERIVATIVE; PROSTAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; EYE BURNING; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OCULAR PRURITUS; PSEUDOEXFOLIATION; TASTE DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; PROBABILITY; PROSTAGLANDINS, SYNTHETIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33947413942     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167688     Document Type: Article

References (29)

1. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19-24
2. Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Exp Opin Invest Drugs 2001;10:721-31
3. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue selections. Exp Eye Res 1998;67:179-91
4. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
5. Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997;41(Suppl 2):S69-75
6. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-8
7. Alm A, Stjemschantz J, for the Scandinavian Latanoprost Study Group. Effects of intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102:1743-1752
8. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily in patients with elevate intraocular pressure. Surv Ophthalmol 2001;45(Suppl 4):S361-8
9. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
10. van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Ophthalmology 2005;112:1177-85
11. Martínez García A, Perez García R. Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma [in Spanish]. Arch Soc Esp Oftalmol 2002;77:269-74
12. Noecker RS, Dirks MS, Choplin NT, et al., for the Bimatoprost/ latanoprost study group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63
13. Heel RC, Brogden RN, Speight TM, et al. Timolol a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979;17:38-55
14. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 2000;17:477-96
15. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1945-51
16. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998;105:1952-9
17. Fechtner R, Airaksinen PJ, Getson AJ, et al. For the Copsopt/ Xalatan study groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (Cosopt™) versus latanoprost 0.005% (Xalatan™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-8
18. Martinez A, Sanchez M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin 2006;22:67-73
19. SPSS (computer program). Version 12.0. SPSS Inc.; Chicago, IL, USA, 2004
20. Watson P, Stjernshantz J. A six-month randomized, double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. The Latanoprost study Group. Ophthalmology 1996;103:126-37
21. Shin DH, Feldman RM, Sheu WO, for the fixed combination latanoprost/timolol study group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111:276-82
22. Parmaksiz S, Yüksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 2006;15:73-80
23. Fechtner RD, Mc Carroll KA, Lines CR, et al. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005;21: 242-9
24. Strohmaier K, Snyder E, DuBiner H, et al. For the dorzolamide/ timolol study group. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998;105:1936-44
25. Konstas AGP, Maltezos A, Bufidis T, et al. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000;14:73-7
26. Coleman AL, Lerner F, Berstein P, et al., for the lumigan/ Cosopt study group. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003;110:2362-8
27. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453-7
28. Liu JH, Zhang X, Kripke DF, et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003;44:1586-90
29. Wax MB, Camras CB, Fiscella RG, et al. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol 2002;133:S1-10